Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert James Gray, Ph.D.

Co-Author

This page shows the publications co-authored by Robert Gray and Keith Flaherty.
Connection Strength

2.523
  1. Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]. Ann Oncol. 2021 Aug; 32(8):1068.
    View in: PubMed
    Score: 0.244
  2. Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clin Cancer Res. 2021 Jun 01; 27(11):2996-3004.
    View in: PubMed
    Score: 0.239
  3. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. JAMA Oncol. 2021 02 01; 7(2):271-278.
    View in: PubMed
    Score: 0.238
  4. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 11 20; 38(33):3883-3894.
    View in: PubMed
    Score: 0.233
  5. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020 10 01; 112(10):1021-1029.
    View in: PubMed
    Score: 0.233
  6. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol. 2020 11 20; 38(33):3895-3904.
    View in: PubMed
    Score: 0.230
  7. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020 07 20; 38(21):2407-2417.
    View in: PubMed
    Score: 0.227
  8. Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). Clin Cancer Res. 2020 04 15; 26(8):1812-1819.
    View in: PubMed
    Score: 0.221
  9. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019 Nov; 30(11):1821-1830.
    View in: PubMed
    Score: 0.221
  10. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol. 2020 01 20; 38(3):214-222.
    View in: PubMed
    Score: 0.219
  11. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019 11 01; 30(11):1821-1830.
    View in: PubMed
    Score: 0.218
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.